Anebulo Pharmaceuticals, Inc.ANEBNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | -3068.11% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +1.17% | +6.30% | +5.71% | +59.11% | +58.43% |
| Weighted Average Shares Diluted Growth | +1.17% | +6.30% | +5.71% | +59.11% | +58.43% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -72.72% | +111.19% | +133.64% | +198.19% | +333.60% |
| Book Value per Share Growth | -77.47% | +116.97% | +155.44% | +92.18% | +223.70% |
| Debt Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| R&D Expense Growth | +3.54% | +14.90% | -14.70% | +140.80% | -38.40% |
| SG&A Expenses Growth | -13.83% | -19.42% | +36.91% | +38.04% | +32.20% |